Gemin X Initiates Phase 2 Clinical Study Of Obatoclax In Combination With Standard Chemotherapy For First-Line Treatment Of Small Cell Lung Cancer

News — By on April 7, 2009 at 6:35 am

Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, announced the initiation of a Phase 2 clinical trial of its lead product candidate obatoclax (GX15-070) for the treatment of patients with extensive-stage small cell lung cancer (SCLC). In this multi-center, randomized, open-label Phase 2 study, clinical effect of a combination of carboplatin, etoposide and obatoclax (the CEO regimen) will be compared to the standard chemotherapeutic therapy of carboplatin and etoposide alone (the control arm) in patients with SCLC. The primary endpoint of the study, expected to enroll approximately 150 patients with SCLC, is comparison of overall response rate (ORR) for the obatoclax-contain…

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback